Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 10 2022 - 8:30AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a clinical-stage oncology-focused cell therapy company today
announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew
Deniger, Ph.D., Vice President, Research & Development at
Alaunos Therapeutics will present at the upcoming H.C. Wainwright
Global Investment Conference being held on May 23-26, 2022 in Miami
Beach, FL.
Details for the presentations are below:
Event: H.C. Wainwright Global
Investment ConferenceDate: Tuesday, May 24,
2022Time: 5:00-5:30 pm
ETLocation: Fontainebleau Miami Beach
HotelRoom: Splash 10
A live webcast of the presentation will be
accessible on the Company’s website in the Investors section under
Events & Presentations at www.alaunos.com or by using the link
here. A replay of the webcast will be available on the Alaunos
website for approximately 90 days following the
presentation. About
Alaunos TherapeuticsAlaunos is a clinical-stage
oncology-focused cell therapy company, focused on developing T-cell
receptor (TCR) therapies based on its proprietary, non-viral
Sleeping Beauty gene transfer technology and its TCR library
targeting shared tumor-specific hotspot mutations in key oncogenic
genes including KRAS, TP53 and EGFR. The Company has clinical and
strategic collaborations with The University of Texas MD Anderson
Cancer Center and the National Cancer Institute. For more
information, please visit www.alaunos.com.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2023 to Apr 2024